Nothing Special   »   [go: up one dir, main page]

UY35903A - Compuestos y composiciones para el tratamiento de enfermedades parasitarias - Google Patents

Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Info

Publication number
UY35903A
UY35903A UY0001035903A UY35903A UY35903A UY 35903 A UY35903 A UY 35903A UY 0001035903 A UY0001035903 A UY 0001035903A UY 35903 A UY35903 A UY 35903A UY 35903 A UY35903 A UY 35903A
Authority
UY
Uruguay
Prior art keywords
compounds
compositions
treatment
present
parasitary
Prior art date
Application number
UY0001035903A
Other languages
English (en)
Inventor
Biggart Agnes
Casey Jacob Nelson Mathison
Advait Suresh Nagle
Molteni Valentina
Yeh Vince
Liang Fang
Supek Frantisek
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52302387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of UY35903A publication Critical patent/UY35903A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula A: o una sal, tautómero, o estereoisómero farmacéuticamente aceptable del mismo, donde las variables son como se definen en este documento. La presente invención proporciona además composiciones farmacéuticas que comprenden tales compuestos y métodos de uso de tales compuestos para tratar, prevenir, inhibir, mejorar, o erradicar la patología y/o sintomatología de una enfermedad causada por un parásito, tal como leishmaniasis, tripanosomiasis africana humana y enfermedad de Chagas.
UY0001035903A 2013-12-19 2014-12-19 Compuestos y composiciones para el tratamiento de enfermedades parasitarias UY35903A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361918089P 2013-12-19 2013-12-19

Publications (1)

Publication Number Publication Date
UY35903A true UY35903A (es) 2015-07-31

Family

ID=52302387

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035903A UY35903A (es) 2013-12-19 2014-12-19 Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Country Status (41)

Country Link
US (6) US9303034B2 (es)
EP (1) EP3083627B1 (es)
JP (1) JP6392352B2 (es)
KR (1) KR102354082B1 (es)
CN (1) CN106029666B (es)
AP (1) AP2016009329A0 (es)
AR (1) AR098844A1 (es)
AU (1) AU2014364565B2 (es)
BR (1) BR112016014004B1 (es)
CA (1) CA2932870C (es)
CL (1) CL2016001421A1 (es)
CR (1) CR20160334A (es)
CU (1) CU24379B1 (es)
CY (1) CY1121060T1 (es)
DK (1) DK3083627T3 (es)
EA (1) EA030823B1 (es)
EC (1) ECSP16067921A (es)
ES (1) ES2701087T3 (es)
GT (1) GT201600131A (es)
HR (1) HRP20182021T1 (es)
HU (1) HUE040254T2 (es)
IL (1) IL246034B (es)
LT (1) LT3083627T (es)
MA (1) MA39186A1 (es)
MX (1) MX368072B (es)
MY (1) MY175865A (es)
NZ (1) NZ721650A (es)
PE (1) PE20160865A1 (es)
PH (1) PH12016501198A1 (es)
PL (1) PL3083627T3 (es)
PT (1) PT3083627T (es)
RS (1) RS58053B1 (es)
SG (1) SG11201604618TA (es)
SI (1) SI3083627T1 (es)
SV (1) SV2016005226A (es)
TN (1) TN2016000253A1 (es)
TW (1) TWI674263B (es)
UA (1) UA117046C2 (es)
UY (1) UY35903A (es)
WO (1) WO2015095477A1 (es)
ZA (1) ZA201604415B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170546A (es) 2015-05-29 2018-04-02 The Univ Of Dundee Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios
SI3331885T1 (sl) * 2015-08-07 2021-03-31 Glaxosmithkline Intellectual Property Development Limited Spojine
WO2017127627A1 (en) 2016-01-21 2017-07-27 The University Of North Carolina At Chapel Hill Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
EP3601233B1 (en) 2017-03-27 2024-08-14 Hydro-Québec Salts for use in electrolyte compositions or as electrode additives
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
TW202028208A (zh) * 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
FR2652085A1 (fr) 1989-09-20 1991-03-22 Science Organisation Nouveau procede de synthese de derives d'oxazolopyridines.
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0643588A (ja) * 1992-07-27 1994-02-18 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3735741B2 (ja) * 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
AU4499697A (en) * 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US20030225036A1 (en) 2000-03-20 2003-12-04 Aleksandr Kolesnikov Non-amidine containing protease inhibitors
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
WO2002036580A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
WO2002038153A1 (en) 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
US20020127605A1 (en) 2000-11-28 2002-09-12 Hamilton Gregory S. Bisubstituted carbocyclic cyclophilin binding compounds and their use
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EP1482928B1 (en) 2001-07-27 2009-09-23 Curis, Inc. Mediators of hedgehog signaling pathways,compositions and uses related thereto
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
DE60228316D1 (en) 2001-11-16 2008-09-25 Nippon Chemiphar Co Xanthinoxidaseinhibitoren
US7622479B2 (en) 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2007500160A (ja) * 2003-07-30 2007-01-11 ラボラトリオス・エセ・ア・エレ・ベ・ア・テ・ソシエダッド・アノニマ 癌の予防および治療のための置換イミダゾピリミジン
US20050256179A1 (en) 2003-08-08 2005-11-17 Sircar Jagadish C Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
CA2538820A1 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005030206A1 (en) 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
AU2005220882A1 (en) 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents
WO2006066914A2 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
JP2008525355A (ja) 2004-12-23 2008-07-17 エフ．ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
JP2009502843A (ja) 2005-07-29 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー アザベンズイミダゾール誘導体、それらの製造、及び抗癌剤としての使用
CN101208339B (zh) 2005-08-01 2010-12-29 霍夫曼-拉罗奇有限公司 杂环苄基氨基衍生物，它们的制备以及作为药剂的应用
AU2006278396A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
EP2054405B1 (en) 2006-07-11 2013-09-18 Daewoong Pharmaceutical Co., Ltd. Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008100376A2 (en) 2007-02-15 2008-08-21 Sirtris Pharmaceuticals, Inc. Truncation variants of sirt1 and methods of use thereof
EP2139474A2 (en) 2007-03-27 2010-01-06 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AR068072A1 (es) 2007-04-19 2009-11-04 Novartis Ag Derivados de bencimidazoles, composiciones farmaceuticas y usos
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
TW200932872A (en) 2007-10-17 2009-08-01 Cheil Ind Inc Novel compound for organic photoelectric device and organic photoelectric device including the same
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
BRPI0917936A2 (pt) 2008-08-25 2017-07-11 Irm Llc Moduladores de via hedgehog
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
UY32776A (es) * 2009-07-09 2011-02-28 Irm Llc Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
BR112012007179B8 (pt) * 2009-09-29 2021-05-25 Univ Texas composto inibidor da di-hidro-orotato desidrogenase, e, formulação farmacêutica
CA2787784A1 (en) * 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
WO2011153377A2 (en) 2010-06-03 2011-12-08 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (cns) injury
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012130633A1 (en) 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
KR102033806B1 (ko) 2011-11-11 2019-10-17 길리어드 아폴로, 엘엘씨 Ａｃｃ 억제제 및 이의 용도
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
CA2866450C (en) * 2012-03-07 2020-02-18 Merck Patent Gmbh Triazolopyrazine derivatives
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
AR091586A1 (es) 2012-06-28 2015-02-11 Fujifilm Corp Derivado de amida o su sal como inhibidor de la produccion de colageno
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014028968A1 (en) 2012-08-21 2014-02-27 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
CA2932870A1 (en) 2015-06-25
US20150175613A1 (en) 2015-06-25
US20160303129A1 (en) 2016-10-20
AU2014364565A1 (en) 2016-07-14
TW201609734A (zh) 2016-03-16
US10596175B2 (en) 2020-03-24
UA117046C2 (uk) 2018-06-11
US9303034B2 (en) 2016-04-05
US20170333437A1 (en) 2017-11-23
TN2016000253A1 (en) 2017-10-06
US20210369716A1 (en) 2021-12-02
DK3083627T3 (da) 2019-01-02
TWI674263B (zh) 2019-10-11
PH12016501198A1 (en) 2016-08-15
RS58053B1 (sr) 2019-02-28
US11123348B2 (en) 2021-09-21
CU20160090A7 (es) 2017-05-10
CU24379B1 (es) 2019-02-04
MX2016008079A (es) 2016-09-16
MA39186A1 (fr) 2017-11-30
CL2016001421A1 (es) 2016-12-30
EA030823B1 (ru) 2018-10-31
US20190000852A1 (en) 2019-01-03
AR098844A1 (es) 2016-06-15
KR102354082B1 (ko) 2022-01-24
CA2932870C (en) 2021-11-09
GT201600131A (es) 2018-12-18
NZ721650A (en) 2018-12-21
MX368072B (es) 2019-09-18
US9700559B2 (en) 2017-07-11
JP2017501177A (ja) 2017-01-12
EA201691271A1 (ru) 2016-12-30
US10085989B2 (en) 2018-10-02
CN106029666A (zh) 2016-10-12
AU2014364565B2 (en) 2017-06-15
HRP20182021T1 (hr) 2019-01-25
BR112016014004A2 (es) 2017-08-08
CN106029666B (zh) 2018-05-18
JP6392352B2 (ja) 2018-09-19
EP3083627A1 (en) 2016-10-26
SV2016005226A (es) 2019-04-23
US20200179391A1 (en) 2020-06-11
PL3083627T3 (pl) 2019-02-28
KR20160093077A (ko) 2016-08-05
BR112016014004B1 (pt) 2022-11-01
HUE040254T2 (hu) 2019-02-28
SI3083627T1 (sl) 2019-01-31
PE20160865A1 (es) 2016-09-03
MY175865A (en) 2020-07-14
WO2015095477A1 (en) 2015-06-25
IL246034A0 (en) 2016-08-02
PT3083627T (pt) 2018-11-30
CY1121060T1 (el) 2019-12-11
ES2701087T3 (es) 2019-02-20
ZA201604415B (en) 2017-09-27
CR20160334A (es) 2016-12-06
SG11201604618TA (en) 2016-07-28
IL246034B (en) 2020-02-27
LT3083627T (lt) 2018-12-27
ECSP16067921A (es) 2017-10-31
AP2016009329A0 (en) 2016-07-31
EP3083627B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY35903A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
GT201600123A (es) Inhibidores de syk
ECSP19030134A (es) Compuesto de piridina
UY36207A (es) Inhibidores de la syk
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CU20130036A7 (es) Triazina-oxidazoles
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
BR112015014349A2 (pt) derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
CR20160600A (es) Quinolizione derivados como inhibidores pi3k
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
EA201792264A1 (ru) Способы лечения воспалительных заболеваний

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230523